PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19385713-1	2009	BACKGROUND AND OBJECTIVE: Bortezomib, an antineoplastic for the treatment of relapsed multiple myeloma and mantle cell lymphoma, undergoes metabolism through oxidative deboronation by cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C19.	Bortezomib	26-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	184-199	
19385713-1	2009	BACKGROUND AND OBJECTIVE: Bortezomib, an antineoplastic for the treatment of relapsed multiple myeloma and mantle cell lymphoma, undergoes metabolism through oxidative deboronation by cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C19.	Bortezomib	26-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	201-204	
19385713-4	2009	The variability of bortezomib pharmacokinetics with CYP enzyme polymorphism was also investigated.	Bortezomib	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-55	
26622646-10	2015	Additional large-scale studies are required in order to evaluate the role of CYP enzymes in bortezomib treatments for patients with multiple myeloma.	Bortezomib	92-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-80